Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2008 Jan 3;8(1):9–16. [Article in French] doi: 10.1016/S1279-7960(04)98154-5

L’usage des corticoïdes en réanimation

Julien Malarewicz, Romain Kirchacker, Djillali Annane ⁎
PMCID: PMC7128403  PMID: 32288522

The content is available as a PDF (191.9 KB).

Références

  • 1.Bright G.M., Darmaun D. Corticosteroid-binding globulin modulates cortisol concentration responses to a given production rate. J Clin Endocrinol Metab. 1995;80:764–769. doi: 10.1210/jcem.80.3.7883828. [DOI] [PubMed] [Google Scholar]
  • 2.Bright G.M. Corticosteroid-binding globulin influences kinetic parameters of plasma cortisol transport and clearance. J Clin Endocrinol Metab. 1995;80:770–775. doi: 10.1210/jcem.80.3.7883829. [DOI] [PubMed] [Google Scholar]
  • 3.Greos L.S., Vichyanond P., Bloedow D.C., et al. Methylprednisolone achieves greater concentrations in the lung than prednisolone. A pharmacokinetic analysis. Am Rev Respir Dis. 1991;144:586–592. doi: 10.1164/ajrccm/144.3_Pt_1.586. [DOI] [PubMed] [Google Scholar]
  • 4.Vichyanond P., Irvin C.G., Larsen G.L., Szefler S.J., Hill M.R. Penetration of corticosteroids into the lung: evidence for a difference between methylprednisolone and prednisolone. J Allergy Clin Immunol. 1989;84:867–873. doi: 10.1016/0091-6749(89)90381-3. [DOI] [PubMed] [Google Scholar]
  • 5.Cavaillon J.M. Rôle des glucocorticoïdes dans la cascade inflammatoire. Reanim Urg. 2000;9:605–612. [Google Scholar]
  • 6.Perretti M., Flower R.J. Modulation of IL-1-induced neutrophil migration by dexamethasone and lipocortin 1. J Immunol. 1993;150:992–999. [PubMed] [Google Scholar]
  • 7.Cronstein B.N., Kimmel S.C., Levin R.I., Martiniuk F., Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA. 1992;89:9991–9995. doi: 10.1073/pnas.89.21.9991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Pitzalis C., Pipitone N., Bajocchi G., et al. Corticosteroids inhibit lymphocyte binding to endothelium and intercellular adhesion: an additional mechanism for their anti-inflammatory and immunosuppressive effect. J Immunol. 1997;158:5007–5016. [PubMed] [Google Scholar]
  • 9.Scheinman R.I., Gualberto A., Jewell C.M., Cidlowski J.A., Baldwin A.S., Jr. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol. 1995;15:943–953. doi: 10.1128/mcb.15.2.943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270:286–290. doi: 10.1126/science.270.5234.286. [DOI] [PubMed] [Google Scholar]
  • 11.De Jonghe B., Sharshar T., Lefaucheur J.P., et al. Groupe de Réflexion et d’Étude des Neuromyopathies en Réanimation Paresis acquired in the intensive care unit: a prospective multicenter study. Jama. 2002;288:2859–2867. doi: 10.1001/jama.288.22.2859. [DOI] [PubMed] [Google Scholar]
  • 12.Lemahieu W.P., Maes B.D., Ghoos Y., Rutgeerts P., Verbeke K., Vanrenterghem Y. Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C] erythromycin breath and urine test. Am J Physiol Gastrointest Liver Physiol. 2003;28:G470–G482. doi: 10.1152/ajpgi.00028.2003. [DOI] [PubMed] [Google Scholar]
  • 13.L’her E. Revision of the 3rd Consensus Conference in Intensive Care and Emergency Medicine in 1988: Management of acute asthmatic crisis in adults and children (excluding infants) Rev Mal Respir. 2002;19:658–665. [PubMed] [Google Scholar]
  • 14.Pauwels R.A., Buist A.S., Ma P., Jenkins C.R., Hurd S.S., GOLD Scientific Committee Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Resp Crit Care Med. 2001;163:1256–1276. doi: 10.1164/ajrccm.163.5.2101039. [DOI] [PubMed] [Google Scholar]
  • 15.Gagnon S., Boota A.M., Fischl M.A., Baier H., Kirksey O.W., La Voie L. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med. 1990;323:1444–1450. doi: 10.1056/NEJM199011223232103. [DOI] [PubMed] [Google Scholar]
  • 16.Nielsen T.L., Eeftinck Schattenkerk J.K., Jensen B.N., et al. Adjunctive corticosteroid therapy for Pneumocystis carinii pneumonia in AIDS: a randomized European multicenter open label study. J Acquir Immune Defic Syndr. 1992;5:726–731. [PubMed] [Google Scholar]
  • 17.Delclaux C., Zahar J.R., Amraoui G., et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis. 1999;29:670–672. doi: 10.1086/598651. [DOI] [PubMed] [Google Scholar]
  • 18.Lebron F., Vassallo R., Puri V., Limper A.H. Pneumocystis carinii Cell Wall {beta}-Glucans Initiate Macrophage Inflammatory Responses through NF-{kappa}B Activation. J Biol Chem. 2003;278:25001–25008. doi: 10.1074/jbc.M301426200. [DOI] [PubMed] [Google Scholar]
  • 19.Barnes P.F., Steele M.A., Young S.M., Vachon L.A. Tuberculosis in patients with human immunodeficiency virus infection. How often does it mimic Pneumocystis carinii pneumonia? Chest. 1992;102:428–432. doi: 10.1378/chest.102.2.428. [DOI] [PubMed] [Google Scholar]
  • 20.Clark T.M., Burman W.J., Cohn D.L., Mehler P.S. Septic Shock From Mycobacterium tuberculosis After Therapy for Pneumocystis carinii. Arch Intern Med. 1998;158:1033–1035. doi: 10.1001/archinte.158.9.1033. [DOI] [PubMed] [Google Scholar]
  • 21.Dooley D.P., Carpenter J.L., Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin Infect Dis. 1997;25:872–887. doi: 10.1086/515543. [DOI] [PubMed] [Google Scholar]
  • 22.Girgis N.I., Farid Z., Kilpatrick M.E., et al. Dexamethasone adjunctive treatment for tuberculous meningitis. Pediatr Infect Dis J. 1991;10:179–183. doi: 10.1097/00006454-199103000-00002. [DOI] [PubMed] [Google Scholar]
  • 23.Alrajhi A.A., Halim M.A., al-Hokail A., Alrabiah F., al-Omran K. Corticosteroid treatment of peritoneal tuberculosis. Clin Infect Dis. 1998;27:52–56. doi: 10.1086/514627. [DOI] [PubMed] [Google Scholar]
  • 24.Lee C.H., Wang W.J., Lan R.S., Tsai Y.H., Chiang Y.C. Corticosteroids in the treatment of tuberculous pleurisy: a double-blind, placebo-controlled, randomized study. Chest. 1988;94:1256–1259. doi: 10.1378/chest.94.6.1256. [DOI] [PubMed] [Google Scholar]
  • 25.Strang J.I., Kakaza H.H., Gibson D.G., et al. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet. 1987;2:1418–1422. doi: 10.1016/s0140-6736(87)91127-5. [DOI] [PubMed] [Google Scholar]
  • 26.Strang J.I., Kakaza H.H., Gibson D.G., et al. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet. 1988;2:759–764. doi: 10.1016/s0140-6736(88)92415-4. [DOI] [PubMed] [Google Scholar]
  • 27.Bukharie H. Paradoxical response to anti-tuberculous drugs: resolution with corticosteroid therapy. Scand J Infect Dis. 2000;32:96–97. doi: 10.1080/00365540050164326. [DOI] [PubMed] [Google Scholar]
  • 28.Yates D., Roberts I. Corticosteroids in head injury. Br Med J. 2000;321:128–129. doi: 10.1136/bmj.321.7254.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Murray G.D., Teasdale G.M., Roberts I., et al. Quality of randomised controlled trials in head injury. Br Med J. 2000;321:1223–1233. [PMC free article] [PubMed] [Google Scholar]
  • 30.Gajdos P. Treatment of myasthenia: role of corticoids and immunosuppressive agents. Press Med. 1999;28:587–589. [PubMed] [Google Scholar]
  • 31.Meade M.O., Guyatt G.H., Cook D.J., Sinuff T., Butler R. Trials of corticosteroids to prevent postextubation airway complications. Chest. 2001;120:464S–468S. doi: 10.1378/chest.120.6_suppl.464s. [DOI] [PubMed] [Google Scholar]
  • 32.Annane D., Aegerter P., Jars-Guincestre M.C., Guidet B., CUB-Rea Network Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med. 2003;168:165–172. doi: 10.1164/rccm.2201087. [DOI] [PubMed] [Google Scholar]
  • 33.Bennet I.L., Finland M., et al. Cooperative Study Group The effectiveness of hydrocortisone in the management of severe infections. Jama. 1963;183:462–465. [Google Scholar]
  • 34.Klastersky J., Cappel R., Debusscher L. Effectiveness of betamethasone in management of severe infections. N Engl J Med. 1971;284:1248–1250. doi: 10.1056/NEJM197106032842206. [DOI] [PubMed] [Google Scholar]
  • 35.Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg. 1976;184:333–341. doi: 10.1097/00000658-197609000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Thompson W.L., Gurley H., Lutz B., et al. Inefficacy of corticosteroids in shock. Clin Res. 1976;24:258A. [Google Scholar]
  • 37.Lucas C.E., Ledgerwood A.M. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch Surg. 1984;119:537–541. doi: 10.1001/archsurg.1984.01390170037008. [DOI] [PubMed] [Google Scholar]
  • 38.Sprung C.L., Caralis P.V., Marcial E.H., et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med. 1984;311:1137–1143. doi: 10.1056/NEJM198411013111801. [DOI] [PubMed] [Google Scholar]
  • 39.Bone R.C., Fisher C.J., Jr., Clemmer T.P., Slotman G.J., Metz C.A., Balk R.A. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653–658. doi: 10.1056/NEJM198709103171101. [DOI] [PubMed] [Google Scholar]
  • 40.The veterans Administration Systemic Sepsis Cooperative Study Group Effect of high dose glucocorticosteroid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987;317:659–665. doi: 10.1056/NEJM198709103171102. [DOI] [PubMed] [Google Scholar]
  • 41.Luce J.M., Montgomery A.B., Marks J.D., Turner J., Metz C.A., Murray J.F. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Respir Dis. 1988;138:62–68. doi: 10.1164/ajrccm/138.1.62. [DOI] [PubMed] [Google Scholar]
  • 42.Cronin L., Cook D.J., Carlet J., Heyland D.K., King D., Lansang M.A., Fisher C.J., Jr. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med. 1995;23:1430–1439. doi: 10.1097/00003246-199508000-00019. [DOI] [PubMed] [Google Scholar]
  • 43.Lefering R., Neugebauer E.A. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. 1995;23:1294–1303. doi: 10.1097/00003246-199507000-00021. [DOI] [PubMed] [Google Scholar]
  • 44.Cooper M.S., Stewart P.M. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003;348:727–734. doi: 10.1056/NEJMra020529. [DOI] [PubMed] [Google Scholar]
  • 45.Bellissant E., Annane D. Effect of hydrocortisone on phenylephrine-mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther. 2000;68:293–303. doi: 10.1067/mcp.2000.109354. [DOI] [PubMed] [Google Scholar]
  • 46.Saito T., Takanashi M., Gallagher E., et al. Corticosteroid effect on early beta-adrenergic down-regulation during circulatory shock: hemodynamic study and beta-adrenergic receptor assay. Intens Care Med. 1995;21:204–210. doi: 10.1007/BF01701473. [DOI] [PubMed] [Google Scholar]
  • 47.Saito T., Fuse A., Gallagher E.T., et al. The effect of methylprednisolone on myocardial beta-adrenergic receptors and cardiovascular function in shock patients. Shock. 1996;5:241–246. doi: 10.1097/00024382-199604000-00002. [DOI] [PubMed] [Google Scholar]
  • 48.Annane D., Sebille V., Troche G., Raphael J.C., Gajdos P., Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. Jama. 2000;283:1038–1045. doi: 10.1001/jama.283.8.1038. [DOI] [PubMed] [Google Scholar]
  • 49.Marik P.E., Zaloga G.P. Adrenal insufficiency during septic shock. Crit Care Med. 2003;31:141–145. doi: 10.1097/00003246-200301000-00022. [DOI] [PubMed] [Google Scholar]
  • 50.Moran J.L., Chapman M.J., O’Fathartaigh M.S., Peisach A.R., Pannall P.R., Leppard P. Hypocortisolaemia and adrenocortical responsiveness at onset of septic shock. Intens Care Med. 1994;20:489–495. doi: 10.1007/BF01711901. [DOI] [PubMed] [Google Scholar]
  • 51.Rothwell P.M., Udwadia Z.F., Lawler P.G. Cortisol response to corticotropin and survival in septic shock. Lancet. 1991;337:582–583. doi: 10.1016/0140-6736(91)91641-7. [DOI] [PubMed] [Google Scholar]
  • 52.McKee J.I., Finlay W.E. Cortisol replacement in severely stressed patients. Lancet. 1983;1:484. doi: 10.1016/s0140-6736(83)91489-7. [DOI] [PubMed] [Google Scholar]
  • 53.Keh D., Boehnke T., Weber-Cartens S., et al. Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med. 2003;167:512–520. doi: 10.1164/rccm.200205-446OC. [DOI] [PubMed] [Google Scholar]
  • 54.Bollaert P.E., Charpentier C., Levy B., Debouverie M., Audibert G., Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998;26:645–650. doi: 10.1097/00003246-199804000-00010. [DOI] [PubMed] [Google Scholar]
  • 55.Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. Jama. 2002;288:862–871. doi: 10.1001/jama.288.7.862. [DOI] [PubMed] [Google Scholar]
  • 56.Ashbaugh D.G., Bigelow D.B., Petty T.L., Levine B.E. Acute respiratory distress in adults. Lancet. 1967;2:319–323. doi: 10.1016/s0140-6736(67)90168-7. [DOI] [PubMed] [Google Scholar]
  • 57.Meduri G.U., Headley S., Kohler G., et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest. 1995;107:1062–1073. doi: 10.1378/chest.107.4.1062. [DOI] [PubMed] [Google Scholar]
  • 58.Meduri G.U., Kohler G., Headley S., Tolley E., Stentz F., Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest. 1995;108:1303–1314. doi: 10.1378/chest.108.5.1303. [DOI] [PubMed] [Google Scholar]
  • 59.Rocco P.R., Souza A.B., Faffe D.S., et al. Effect of corticosteroid on lung parenchyma remodeling at an early phase of acute lung injury. Am J Respir Crit Care Med. 2003;168:677–684. doi: 10.1164/rccm.200302-256OC. [DOI] [PubMed] [Google Scholar]
  • 60.Weigelt J.A., Norcross J.F., Borman K.R., Snyder W.H. Early steroid therapy for respiratory failure. Arch surg. 1985;120:536–540. doi: 10.1001/archsurg.1985.01390290018003. [DOI] [PubMed] [Google Scholar]
  • 61.Bone R.C., Fisher C.J., Clemmer T.P., Slotman G.J., Metz C.A. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest. 1987;92:1032–1036. doi: 10.1378/chest.92.6.1032. [DOI] [PubMed] [Google Scholar]
  • 62.Bernard G.R., Luce J.M., Sprung C.L., et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987;317:1565–1570. doi: 10.1056/NEJM198712173172504. [DOI] [PubMed] [Google Scholar]
  • 63.Dreyfuss D., Ricard J.D., De Lassence A. Au vu des études cliniques, quels sont les arguments pour l’efficacité des corticoïdes au cours du syndrome de détresse respiratoire aiguë ? Reanim Urg. 2000;9:670–676. [Google Scholar]
  • 64.Meduri G.U., Belenchia J.M., Estes R.J., Wunderink R.G., el Torky M., Leeper K.V., Jr. Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids. Chest. 1991;100:943–952. doi: 10.1378/chest.100.4.943. [DOI] [PubMed] [Google Scholar]
  • 65.Meduri G.U., Headley A.S., Golden E., et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. A randomized controlled trial. Jama. 1998;280:159–165. doi: 10.1001/jama.280.2.159. [DOI] [PubMed] [Google Scholar]
  • 66.Herridge M.S., Cheung A.M., Tansey C.M., et al. Canadian Critical Care Trials Group One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003;348:683–693. doi: 10.1056/NEJMoa022450. [DOI] [PubMed] [Google Scholar]
  • 67.De Gans J., Van De Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347:1549–1556. doi: 10.1056/NEJMoa021334. [DOI] [PubMed] [Google Scholar]
  • 68.Xie J., Han Y., Li T.S., et al. Dynamic changes of plasma cytokine levels in patients with severe acute respiratory syndrome. Zhonghua Nei Ke Za Zhi. 2003;42:643–645. Chinese. [PubMed] [Google Scholar]
  • 69.Li Z., Guo X., Hao W., et al. The relationship between serum interleukins and T-lymphocyte subsets in patients with severe acute respiratory syndrome. Chin Med J. 2003;116:981–984. [PubMed] [Google Scholar]
  • 70.Beijing Group of National Research Project for SARS Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome. Chin Med J. 2003;116:1283–1287. [PubMed] [Google Scholar]
  • 71.Ho J.C., Ooi G.C., Mok T.Y., et al. High dose pulse versus non-pulse corticosteroid regimens in Severe Acute Respiratory Syndrome. Am J Respir Crit Care Med. 2003;168:1449–1456. doi: 10.1164/rccm.200306-766OC. [DOI] [PubMed] [Google Scholar]
  • 72.Li N., Ma J., Nie L., et al. Retrospective analysis of the corticosteroids treatment on severe acute respiratory syndrome (SARS) Beijing Da Xue Xue Bao. 2003;35(Suppl):16–18. Chinese. [PubMed] [Google Scholar]
  • 73.So L.K., Lau A.C., Yam L.Y., et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet. 2003;361:1615–1617. doi: 10.1016/S0140-6736(03)13265-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Le Praticien En Anesthesie Reanimation are provided here courtesy of Elsevier

RESOURCES